Fig. 4

Clinical outcomes for Nrf2-activating mutations in NSCLC patients from TCGA cohort. (A) Kaplan–Meier survival curves of OS between NFE2L2 MU and WT groups from LUAD. datasets. (B) The prevalence of Nrf2-activating mutations and Nrf2-inactivating mutations in each cancer type. (C) The proportion of Nrf2-activating mutations and Nrf2-inactivating mutations in LUAD and LUSC. Kaplan–Meier survival curves of OS among Nrf2-activating MU, Nrf2-inactivating MU, unknown NFE2L2 MU and WT groups from LUAD (D) and LUSC (E). (F) Kaplan–Meier survival curves of OS among HTMB NFE2L2 MU, HTMB NFE2L2 WT, LTMB NFE2L2 MU and LTMB NFE2L2 WT patients with NSCLC from TCGA cohort. HTMB: high tumor mutation burden, L TMB: Low tumor mutation burden. (G) The multivariate Cox regression analysis for OS in patients with LUAD. CNA: copy number alteration; MSI: microsatellite instability; OS: overall survival